OBJECTIVE： To evaluate the clinical efficacy and safety of Wenxin granules in the adjuvant treatment of unstable angina pectoris （UAP）. METHODS： Retrieved from PubMed， Embase， Cochrane library， CBM， CNKI， VIP， Wanfang database， etc.， randomized controlled trials （RCTs） about Wenxin granules combined with routine Western medicine （trial group） versus routine Western medicine （control group） in the treatment of UAP were collected. The methodological quality of included studies was evaluated by using Cochrane bias risk assessment tool 5.0.1. The data were extracted and Meta-analyzed was performed on by using Rev Man 5.2 software. Funnel plot， Egger’s test and non-parameter trim and filling method were used to evaluate publication bias. TSA 0.9 software was used for trial sequential analysis （TSA）. RESULTS： A total of 30 RCTs were included， involving 3 405 patients. Total response rate of angina pectoris [RR＝1.21， 95％CI（1.17，1.24），P＜0.001] and ECG [RR＝1.26， 95％CI（1.17，1.35）， P＜0.001）] in trial group were significantly better than control group. Subgroup analysis of different treatment courses showed that total response rate of angina pectoris and ECG in trial group were significantly higher than control group （P＜0.05）. There was no statistical significance in the incidence of ADR （P＞0.05）. The results of Funnel plot and Egger’s linear regression showed that there was certain publication bias in related studies about total response rate of angina pectoris， but the ECG total response rate related research publication bias is small. The results of sensitivity analysis and trim and filling method were stable and reliable. TSA suggested that there was definite therapeutic efficacy evidence for Wenxin granules combined with routine Western medicine in the treatment of UAP. CONCLUSIONS： Wenxin granules combined with routine Western medicine is safe and effective for UAP.